TG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

TG Therapeutics

03/08/2026 14:31

TG Therapeutics Inc TGTX.OQ reported quarterly adjusted earnings of 5 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 17 cents.  The mean expectation of seven analysts for the quarter was for earnings of 34 cents per share. Wall Street expected results to range from -7 cents to 61 cents per share.
Revenue rose 70.3% to $240.34 million from a year ago; analysts expected $229.72 million. 
TG Therapeutics Inc's reported EPS for the quarter was 5 cents​.
The company reported quarterly net income of $7.78 million.
TG Therapeutics Inc shares had fallen by 5.3% this quarter and gained 74.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4.4% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for TG Therapeutics Inc is $74.00, about 29.7% above its last closing price of $52.03
This summary was machine generated from LSEG data August 3 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.34
0.05
Missed
Mar. 31 2026 
0.29
0.18
Missed
Dec. 31 2025 
0.35
0.14
Missed
Sep. 30 2025 
0.22
0.16
Missed